The stability of gross margin near 91% underscores the low marginal cost of manufacturing specialty CNS drugs, but the real story is the operating margin recovery. The 14-percentage-point swing in operating margin between Q1 and Q2 2026 suggests that the company is gaining traction in controlling SG&A relative to revenue, a trend that may continue if Daybue's launch scales. However, the net margin of 10.2% in 2026Q2 is still modest for a biotech with such high gross margins, indicating that the cost structure remains heavy with R&D and commercialization expenses. Investors should monitor whether the operating leverage is sustainable or if it reflects one-time cost controls.

The return on invested capital has been volatile, with a spike to 24.6% in 2024Q4 driven by a one-time gain, but the underlying trend shows a gradual improvement from negative territory in early 2026. The 2026Q2 ROIC of 2.8% is still far below the cost of capital, suggesting that the company is not yet generating economic profits on its invested capital. The improvement is driven by margin expansion rather than asset efficiency, as asset turnover has remained low at 0.18. This implies that the company's capital base is growing faster than its operating income, a common pattern for commercial-stage biotechs investing in pipeline and infrastructure. The key question is whether the recent revenue acceleration can translate into sustained ROIC above the cost of capital.

The cash conversion cycle has been highly volatile, ranging from 58 to 275 days over the past ten quarters, reflecting the lumpy nature of specialty pharmaceutical sales and inventory management. The recent improvement to 58 days is notable, as it suggests better alignment between receivables collection, inventory holding, and supplier payments. However, the DSO of 46 days and DIO of 103 days remain elevated, indicating that the company may be carrying excess inventory or facing slower collections from payers. The extension of DPO to 91 days suggests the company is leveraging supplier terms to fund operations, which may not be sustainable if suppliers tighten credit. Investors should watch whether the CCC can stabilize at lower levels, as working capital swings have historically distorted cash flow.

ACAD's leverage is minimal, with total debt of $73.9 million against a growing equity base, resulting in a D/E ratio of 0.06. The D/EBITDA ratio of 1.80 is modest, suggesting that the company's debt service is comfortable, though interest coverage data is unavailable. The low leverage provides strategic flexibility, allowing the company to fund pipeline development or potential acquisitions without immediate refinancing risk. However, the company has historically relied on equity financing, and if cash reserves dwindle, future dilution could be a concern. The recent improvement in cash flow and the strong balance sheet position suggest that the company is not under financial stress, but the lack of interest coverage data warrants monitoring.

The current ratio has steadily improved over the past two years, reaching 3.39 in 2026Q2, indicating that current assets comfortably cover current liabilities. The quick ratio of 3.30 suggests that the liquidity is not dependent on inventory, which is a positive sign for a company with high inventory days. Cash and cash equivalents have more than doubled since 2024Q1, providing a strong buffer against operational shocks or unexpected clinical trial costs. However, the company's reliance on U.S. reimbursement and the potential for Medicare price negotiation could pressure cash flows in the future. The strong liquidity position suggests that the company can weather near-term uncertainties, but investors should monitor whether the cash balance is being deployed efficiently.